Hematology — polycythemia vera; siRNA, iron regulation and acquisition economicsNovember 11, 2026

Merck KGaA’s $1.3 Billion Silence Deal: What Quarterly Divesiran Still Has to Prove

SLN

Executive Summary

Merck KGaA’s proposed Silence acquisition puts quarterly divesiran at the center of a $1.3 billion equity-value deal. The key question is whether its twelve-week regimen can deliver sustained hematocrit control and a useful position alongside approved rusfertide. We examine the Phase 2 evidence, valuation terms and remaining clinical and commercial risks.

Evidence reviewed through November 11, 2026

Merck KGaA, Darmstadt, Germany agreed on October 19 to acquire Silence Therapeutics for $20 per ADS in cash. The announcement assigns approximately $1.3 billion of equity value and $1.1 billion of enterprise value to the transaction. Closing is expected in the first quarter of 2027, subject to approvals and other conditions.[1]

The offer represents a 130% premium to the October 16 closing ADS price and an 82% premium to the preceding 30-day volume-weighted average.[1] Those are different reference points, not competing descriptions of the offer.

The investment question is whether divesiran can turn a long dosing interval into a useful clinical and commercial position in polycythemia vera, or PV. The acquisition premium cannot answer that question. Neither can a pooled Phase 2 response rate on its own.

The regimen matters more than the headline

Silence’s 48-patient, randomized SANRECO Phase 2 study reported an 88% response rate for pooled divesiran groups versus 19% for placebo. Response required hematocrit below 45% without phlebotomy during weeks 18–36. The six-week and twelve-week groups achieved 93.8% and 81.3%, respectively.[2]

The relevant distinction is straightforward: the proposed Phase 3 regimen is every twelve weeks. Investors underwriting that regimen should focus on its own result rather than assign the pooled 88% rate to quarterly treatment.

The difference between the two active groups should not be treated as proof that one schedule is superior. A small trial provides limited precision. It does, however, make regimen selection an essential part of diligence: how consistently does control persist until the next dose, and which patients need additional intervention?

Why an iron-control drug can matter

PV involves abnormal blood-cell production. Phlebotomy and cytoreductive treatment are used to control hematocrit, while repeated blood removal can contribute to iron-deficiency symptoms and treatment burden.[3]

Divesiran silences liver TMPRSS6 to increase endogenous hepcidin and restrict iron available for red-cell production.[4] Its mechanism supports a hematocrit-control thesis. It does not, by itself, establish modification of the malignant clone or improved survival.

That distinction matters for valuation. A drug can create substantial value by making chronic management easier. There is no need to assume disease modification to make that case, and no basis to price in that stronger claim without evidence.

Quarterly dosing is a proposition to test

The competitive baseline has changed. FDA approved the hepcidin mimetic rusfertide, branded Mimrylo, on August 28, 2026.[5] Its prescribing information uses weekly administration with dose adjustment.[6]

Mimrylo / rusfertide: A hepcidin mimetic peptide, approved in the U.S., with weekly dosing adjusted to response.

Divesiran: An investigational TMPRSS6-targeting siRNA, with every-twelve-week dosing proposed for Phase 3.

Sources: [2,4–6]. This is a comparison of development status and treatment approach, not a ranking of efficacy or safety.

My interpretation is that this creates both an opportunity and a higher competitive hurdle. An established treatment can help define clinical demand. It also means that an eventual entrant must offer a reason to be selected within an existing care pathway.

Less frequent administration could be that reason, provided efficacy persists and the safety profile supports continued use. Merck’s announcement describes two Grade 1 anemia cases assessed by an investigator as treatment-related.[8] A 48-patient study cannot establish the limits of long-term or rare toxicity.

Injection frequency is only one part of treatment burden. Monitoring, rescue phlebotomy, dose adjustment, access and patient preference all belong in the assessment. Fewer injections should not be equated automatically with proportionately fewer visits or lower total cost.

Nor should response rates from different trials be placed in a league table. Entry criteria, treatment background, endpoint definitions and assessment windows can change the apparent result. A commercial comparison requires more than a numerical contrast between separate placebo-controlled studies.

Cash consideration does not eliminate development risk

The deal’s equity value and enterprise value describe different things. They should not be added together. The headline price also buys a company, rather than providing a disclosed standalone valuation for divesiran.[1]

For a buyer, the relevant economic exposure extends beyond acquisition consideration to the work needed to obtain an approval and build a business. Trial execution, manufacturing, launch investment and the time before meaningful cash generation still matter. Any valuation model should state those assumptions rather than allow the acquisition announcement to stand in for them.

Similarly, all-cash consideration describes what sellers would receive if the transaction closes. It does not mean shareholders have already been paid, or that the buyer has removed clinical uncertainty. The deal changes who bears future development risk.

What would strengthen or weaken the thesis?

Can the quarterly regimen maintain control? Reproducible results with sustained control across the dosing interval would strengthen the case. Frequent rescue treatment or loss of control before redosing would weaken it.

Does convenience reach patients? Fewer procedures with meaningful symptom or functional improvement would strengthen the case. Injection savings offset by additional care burden would weaken it.

Is chronic use manageable? Consistent longer-term safety and clear adjustment strategies would strengthen the case. Toxicity or management difficulty that limits persistence would weaken it.

Can differentiation support adoption? A clear patient segment and workable reimbursement would strengthen the case. Limited clinical distinction or restrictive access would weaken it.

These are analytical criteria, not reported trial findings or company forecasts. They make the investment case testable without inventing a peak-sales estimate.

The next evidence checkpoint

Silence has scheduled a SANRECO Phase 2 oral presentation for December 14 at ASH 2026.[7] Its disclosed development plan anticipates Phase 3 initiation in the first half of 2027.[2] A presentation announcement is not a completed data presentation, and a development plan is not a trial start.

The present case supports continued development of a potentially differentiated chronic treatment. The acquisition should be judged by whether that differentiation survives larger trials and becomes useful in practice. Merck KGaA is paying to pursue that outcome; the purchase price does not establish it.

Primary sources

  1. Silence acquisition announcement, October 19, 2026, SEC Exhibit 99.1.

  2. Silence, SANRECO Phase 2 topline results, August 10, 2026. Company-reported results; endpoint wording follows the announcement’s Key findings section.

  3. NCI, Myeloproliferative Neoplasms Treatment (PDQ), PV section.

  4. Silence, Divesiran pipeline page.

  5. FDA, Mimrylo approval announcement, August 28, 2026.

  6. FDA, Mimrylo initial prescribing information, August 2026.

  7. Silence, ASH presentation announcement, November 4, 2026.

  8. Merck KGaA, acquisition announcement, October 19, 2026.

BioScore

5.8/10
Watchlist